A simple method for the detection of abnormal brain regions in Alzheimer’s disease patients using [11C]MP4A: Comparison with [123I]IMP SPECT
- 46 Downloads
We have developed a radiolabeled lipophilic acetylcholine analogue, N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) to measure brain acetylcholinesterase (AChE) activity by positron emission tomography (PET)in vivo. Aiming to develop a new SPECT tracer similar to MP4A, we first proposed a simple method for diagnosing Alzheimer’s disease (AD) using [11C]MP4A PET. We performed [11C]MP4A PET and N-isopropyl [123I]iodoamphetamine ([123I]IMP) SPECT in 13 patients with AD and in 17 normal controls (NC). We calculated the ratio of radioactivity of the cortical region of interest (ROI) to that of the cerebellum measured with [11C]MP4A PET (MP4A ratio) and the ratio of regional cerebral blood flow (rCBF) to that of the cerebellum measured with [123I]IMP SPECT (IMP ratio). Eleven cortical ROIs were placed in the frontal, sensorimotor, temporal, parietal, and occipital cortices in both hemispheres and in the posterior cingulate cortex, and z-score was calculated in each ROI in patients with AD compared with NC. When the z-score was 2 or more in a ROI, it was defined as a positive ROI. When a patient had 3 or more positive ROIs, the patient was diagnosed as having AD. The reduction in the MP4A ratio was greater than that in the IMP ratio in all cortical ROIs except for in the right parietal cortex and cingulate cortex in patients with AD. MP4A ratio method showed 92% sensitivity and the IMP ratio method 69% sensitivity for the diagnosis of AD. These results encourage us to develop a new SPECT tracer similar to MP4A for the diagnosis of AD.
Key words[11C]MP4A PET [123I]IMP SPECT Comparison Alzheimer’s disease simple ratio analysis
Unable to display preview. Download preview PDF.
- 2.Arai H, Kosaka K, Muramoto O, Iizuka R. A biological study of cholinergic neurons in the post-mortem brains from patients with Alzheimer-type dementia.Clin Neurol 1984; 24: 1128–1135.Google Scholar
- 3.Gsell W, Strein I, Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared.J Neural Transm 1996; 47(Suppl): 73–101.Google Scholar
- 5.Tanaka N, Fukushi K, Shinotoh H, Nagatsuka S, Namba H, lyo M, et al. Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[11C]methyl- piperidin-4-yl acetate without arterial blood sampling: Methodology of shape analysis and its diagnostic power for Alzheimer’s disease.J Cereb Blood Flow Metab 2001; 21: 295–301.PubMedCrossRefGoogle Scholar
- 6.Nagatsuka S, Fukushi K, Shinotoh H, Namba H, lyo M, Tanaka N, et al. Kinetic analysis of [11C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling.J Cereb Blood Flow Metab 2001; 21: 1354–1366.CrossRefGoogle Scholar
- 8.Koeppe RA, Kird A, Frey KA, Snyder P, Meyer MR, Kilbourn, et al. Kinetic modeling of N-[11C]methylpiperidin-4-yl propinate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain.J Cereb Blood Flow Metab 1999; 19: 1150–1163.PubMedCrossRefGoogle Scholar
- 14.Ohkubo M, Odano I, Takahashi N, Takahashi M, Ohtaki H, Noguchi E, et al. A study on accuracy of rCBF measurement using the conventional microsphere method withN-isopropyl-p-iodine-[123I]iodoamphetamine and SPECT.KAKU IGAKU (Jpn J Nucl Med) 1995; 32: 147–151.Google Scholar
- 15.Namba H, Yanagisawa M, Togawa T, Kinoshita F, Sueyoshi K, Yui N. Quantitative measurement of cerebral blood flow by the microsphere model with super-early123I-IMP brain SPECT.KAKU IGAKU (Jpn J Nucl Med) 1997; 34: 1027–1031.Google Scholar
- 16.Ikenaga H, Yanagimoto S, Ono S, Tomomitsu T, Mimura H, Morita K, et al. Study of some parameters to calculate regional cerebral blood with microsphere model using N-isopropyl-p-[123l] iodoamphetamine.KAKU IGAKU (Jpn J Nud Med) 1991; 28: 1187–1191.Google Scholar
- 23.Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Jonker C. The diagnostic value of magnetic resonance imaging and technetium-99m-HMPAO single photon emission computed tomography for the diagnosis of Alzheimer disease in a community—Dwelling elderly population.Alzheimer Dis Assoc Disord 1997; 11: 63–70.PubMedCrossRefGoogle Scholar
- 24.Hanyu H, Nakano S, Abe S, Arai H, Iwamoto T, Takasaki M. Neuroimaging in the diagnosis of Alzheimer’s disease.Jpn J Geriat 1994; 31: 683–689.Google Scholar